SECONDARY PREVENTION IN PATIENTS AFTER MYOCARDIAL INFARCTION AT AMBULATORY SPECIALIZED CARDIOLOGY INSTITUTION (PHARMACOEPIDEMIOLOGY STUDY)

Aim. To assess 5 years trend in level of doctor’s adherence to actual guidelines on secondary prevention of cardiovascular diseases in patients with a history of myocardial infarction in ambulatory specialized healthcare institution in Moscow. Material and methods. There were 752 patients firstly vi...

Full description

Saved in:
Bibliographic Details
Main Authors: S. B. Fitilev, I. I. Shkrebneva, A. V. Vozzhaev, D. A. Dimitrova
Format: Article
Language:English
Published: Столичная издательская компания 2017-05-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:https://www.rpcardio.online/jour/article/view/1441
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849227745060454400
author S. B. Fitilev
I. I. Shkrebneva
A. V. Vozzhaev
D. A. Dimitrova
author_facet S. B. Fitilev
I. I. Shkrebneva
A. V. Vozzhaev
D. A. Dimitrova
author_sort S. B. Fitilev
collection DOAJ
description Aim. To assess 5 years trend in level of doctor’s adherence to actual guidelines on secondary prevention of cardiovascular diseases in patients with a history of myocardial infarction in ambulatory specialized healthcare institution in Moscow. Material and methods. There were 752 patients firstly visited healthcare institution in 2006 and 825 patients – in 2011. Their data was included in two-stage retrospective pharmacoepidemiology study. Results. Prescription rate significantly increased for three of four prophylactic groups recommended for patients with a history of myocardial infarction (antiplatelets – 91.76%, beta-blockers – 83.39%, statins – 69.45%). When assessing prescribed doses of drugs, an increase in a number of their higher doses prescriptions was revealed (at the second stage of the study acetylsalicylic acid 100 mg/day received 75.32% of patients, enalapril 20 mg/day – 30.45%, simvastatin and atorvastatin 20 mg/day – 64.52% and 47.89% of patients, respectively). Conclusion. Results showed growing level of doctor’s adherence to actual recommendations on therapy and secondary prevention of cardiovascular diseases. Nevertheless, the level of adherence remains unsatisfactory and requires additional work with doctors.
format Article
id doaj-art-a33fde2aa2de4182945d28eb91b66f57
institution Kabale University
issn 1819-6446
2225-3653
language English
publishDate 2017-05-01
publisher Столичная издательская компания
record_format Article
series Рациональная фармакотерапия в кардиологии
spelling doaj-art-a33fde2aa2de4182945d28eb91b66f572025-08-23T10:00:28ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532017-05-0113217117710.20996/1819-6446-2017-13-2-171-1771324SECONDARY PREVENTION IN PATIENTS AFTER MYOCARDIAL INFARCTION AT AMBULATORY SPECIALIZED CARDIOLOGY INSTITUTION (PHARMACOEPIDEMIOLOGY STUDY)S. B. Fitilev0I. I. Shkrebneva1A. V. Vozzhaev2D. A. Dimitrova3Peoples’ Friendship University of RussiaPeoples’ Friendship University of RussiaPeoples’ Friendship University of RussiaPeoples’ Friendship University of RussiaAim. To assess 5 years trend in level of doctor’s adherence to actual guidelines on secondary prevention of cardiovascular diseases in patients with a history of myocardial infarction in ambulatory specialized healthcare institution in Moscow. Material and methods. There were 752 patients firstly visited healthcare institution in 2006 and 825 patients – in 2011. Their data was included in two-stage retrospective pharmacoepidemiology study. Results. Prescription rate significantly increased for three of four prophylactic groups recommended for patients with a history of myocardial infarction (antiplatelets – 91.76%, beta-blockers – 83.39%, statins – 69.45%). When assessing prescribed doses of drugs, an increase in a number of their higher doses prescriptions was revealed (at the second stage of the study acetylsalicylic acid 100 mg/day received 75.32% of patients, enalapril 20 mg/day – 30.45%, simvastatin and atorvastatin 20 mg/day – 64.52% and 47.89% of patients, respectively). Conclusion. Results showed growing level of doctor’s adherence to actual recommendations on therapy and secondary prevention of cardiovascular diseases. Nevertheless, the level of adherence remains unsatisfactory and requires additional work with doctors.https://www.rpcardio.online/jour/article/view/1441secondary preventionantiplateletsstatinsace inhibitorsbeta-blockerspharmacoepidemiology
spellingShingle S. B. Fitilev
I. I. Shkrebneva
A. V. Vozzhaev
D. A. Dimitrova
SECONDARY PREVENTION IN PATIENTS AFTER MYOCARDIAL INFARCTION AT AMBULATORY SPECIALIZED CARDIOLOGY INSTITUTION (PHARMACOEPIDEMIOLOGY STUDY)
Рациональная фармакотерапия в кардиологии
secondary prevention
antiplatelets
statins
ace inhibitors
beta-blockers
pharmacoepidemiology
title SECONDARY PREVENTION IN PATIENTS AFTER MYOCARDIAL INFARCTION AT AMBULATORY SPECIALIZED CARDIOLOGY INSTITUTION (PHARMACOEPIDEMIOLOGY STUDY)
title_full SECONDARY PREVENTION IN PATIENTS AFTER MYOCARDIAL INFARCTION AT AMBULATORY SPECIALIZED CARDIOLOGY INSTITUTION (PHARMACOEPIDEMIOLOGY STUDY)
title_fullStr SECONDARY PREVENTION IN PATIENTS AFTER MYOCARDIAL INFARCTION AT AMBULATORY SPECIALIZED CARDIOLOGY INSTITUTION (PHARMACOEPIDEMIOLOGY STUDY)
title_full_unstemmed SECONDARY PREVENTION IN PATIENTS AFTER MYOCARDIAL INFARCTION AT AMBULATORY SPECIALIZED CARDIOLOGY INSTITUTION (PHARMACOEPIDEMIOLOGY STUDY)
title_short SECONDARY PREVENTION IN PATIENTS AFTER MYOCARDIAL INFARCTION AT AMBULATORY SPECIALIZED CARDIOLOGY INSTITUTION (PHARMACOEPIDEMIOLOGY STUDY)
title_sort secondary prevention in patients after myocardial infarction at ambulatory specialized cardiology institution pharmacoepidemiology study
topic secondary prevention
antiplatelets
statins
ace inhibitors
beta-blockers
pharmacoepidemiology
url https://www.rpcardio.online/jour/article/view/1441
work_keys_str_mv AT sbfitilev secondarypreventioninpatientsaftermyocardialinfarctionatambulatoryspecializedcardiologyinstitutionpharmacoepidemiologystudy
AT iishkrebneva secondarypreventioninpatientsaftermyocardialinfarctionatambulatoryspecializedcardiologyinstitutionpharmacoepidemiologystudy
AT avvozzhaev secondarypreventioninpatientsaftermyocardialinfarctionatambulatoryspecializedcardiologyinstitutionpharmacoepidemiologystudy
AT dadimitrova secondarypreventioninpatientsaftermyocardialinfarctionatambulatoryspecializedcardiologyinstitutionpharmacoepidemiologystudy